Biotech Values

[DewDiligence]

Drug Sales vs Population by Geography

Big Pharma’s newfound interest in so-called emerging markets
is not a smokescreen to divert investors’ attention from clinical
failures and expiring patents. To the contrary, there’s serious
money to be made in emerging markets—especially in the six
BRIC-MT* countries, which have a growing middle class that
wants prescription drugs and has the means to pay for them.
The growth potential is obvious: BRIC-MT countries comprise
45% of the world’s population but only 10% of worldwide
expenditures on prescription drugs.

For related stories, see #msg-33416175, #msg-33184399,
#msg-32316085, #msg-30901607, #msg-38789392,
#msg-35422978, and #msg-33416175.

 
                  Proportion of      Proportion of 
                World Population   World Drug Sales 
 US, EU, Japan        15%                82% 
 BRIC-MT*             45%                10% 
 Rest of world        40%                 8% 

*Brazil, Russia, India, China, Mexico, Turkey.

Source: Sanofi-aventis, IMS.